Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cell

• Publication date

  2004-03-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0092-8674(04)00215-6PMID 15035987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RAS oncogenes: The first 30 years

  2003cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• Lack of BRAF mutation in primary uveal melanoma.

  2003cited by this paper
• Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

  2003cited by this paper
• Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.

  2003cited by this paper
• RAS oncogenes: the first 30 years

  2003cited by this paper
• Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002influential reference
• A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer

  2002cited by this paper
• Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.

  2002cited by this paper
• BRAF and RAS mutations in human lung cancer and melanoma.

  2002cited by this paper
• Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs

  2002cited by this paper
• Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

  2002cited by this paper
• Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP

  2002influential reference
• Design and discovery of small molecules targeting raf-1 kinase.

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002influential reference
• KSR: a MAPK scaffold of the Ras pathway?

  2001cited by this paper
• Discovery of a novel Raf kinase inhibitor.

  2001cited by this paper
• Positive and negative regulation of Raf kinase activity and function by phosphorylation

  2001cited by this paper
• Active Ras induces heterodimerization of cRaf and BRaf.

  2001cited by this paper
• Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.

  2001cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601

  2000cited by this paper
• Disruption of the 14-3-3 Binding Site within the B-Raf Kinase Domain Uncouples Catalytic Activity from PC12 Cell Differentiation*

  2000cited by this paper
• Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.

  2000cited by this paper
• Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

  2000cited by this paper
• Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation

  1999influential reference
• Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C.

  1998cited by this paper
• Crystallography & NMR system: A new software suite for macromolecular structure determination.

  1998cited by this paper
• Kinetic analyses of mutations in the glycine-rich loop of cAMP-dependent protein kinase.

  1998cited by this paper
• The complexity of Raf-1 regulation.

  1997cited by this paper
• Mitogen-activated protein kinase pathways.

  1997cited by this paper
• Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases*

  1997cited by this paper
• Active and inactive protein kinases: structural basis for regulation.

  1996cited by this paper
• Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization

  1996cited by this paper
• Oligomerization activates c-Raf-1 through a Ras-dependent mechanism

  1996cited by this paper
• Bone morphogenetic protein-4 (BMP-4) acts during gastrula stages to cause ventralization of Xenopus embryos.

  1996cited by this paper
• Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.

  1995cited by this paper
• 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras-independent manner

  1995cited by this paper
• Selection of activating mutations of c-fms in FDC-P1 cells.

  1995cited by this paper
• Crystal structure of the tyrosine kinase domain of the human insulin receptor

  1994cited by this paper
• Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase

  1993cited by this paper
• Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system.

  1993cited by this paper
• Activation of extracellular signal‐regulated kinase, ERK2, by p21ras oncoprotein.

  1992cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• A whole-mount immunocytochemical analysis of the expression of the intermediate filament protein vimentin in Xenopus.

  1989cited by this paper
• Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus.

  1983cited by this paper
• Normal Table of Xenopus Laevis

  1968cited by this paper
• Normal Table of Xenopus Laevis (Daudin)

  1958cited by this paper

• Unveiling a new SORBS2::BRAF fusion in papillary thyroid carcinoma: insights from molecular diagnostics.

  2026cites this paper
• New pyrimidine derivatives as potential agents against hepatocellular carcinoma: design, synthesis, and in vitro and in vivo biological evaluations

  2026cites this paper
• A neuron subtype-specific role of MEK-ERK signaling in axon survival via transcriptional regulation of Nmnat2.

  2026cites this paper
• Onconase Induces Apoptosis in Dabrafenib-Resistant Melanoma Cell Lines Through Dysregulation of ROS Homeostasis, Antioxidant Protein Expression, and Mitochondrial Dynamics.

  2026cites this paper
• Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities

  2026cites this paper
• The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers

  2026cites this paper
• DDX21 Links <i> BRAF ^V600E </i> and TERT to Promote Thyroid Cancer Progression

  2026cites this paper
• KRAS Inhibition in Pancreatic Ductal Adenocarcinoma

  2026cites this paper
• Sox9-dependent acquisition of a drug resistant "memory state" induces reciprocal expression of Sox6 and Sox7 in BRAF melanoma.

  2026cites this paper
• Signal Peptide-CUB-EGF-like Domain-Containing Protein 3 (SCUBE3): From Molecule to Therapy

  2026cites this paper
• Eosinophilic Cells in Endometrial Carcinoma as a Predictor of BRAF Mutation: Report of 2 Cases.

  2026cites this paper
• Current Perspectives on Pediatric Low-Grade Gliomas: Focus on BRAF and MEK Inhibition

  2026cites this paper
• Diffuse low-grade glioma with a rare BRAF p.T599dup mutation in a child: importance of clinicopathological and molecular correlation.

  2026cites this paper
• Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.

  2025cites this paper
• Nomogram model based on ultrasonography and contrast-enhanced CT for predicting BRAFV600E mutation in thyroid nodules classified as C-TIRADS 3 and above

  2025cites this paper
• Molecular docking and dynamics simulations of 4-heteroarylidenamino-4,5-dihydro-1H-1,2,4-triazol-5-one derivatives as potential anticancer agents

  2025cites this paper
• Sinonasal Mucosal Melanoma: A Comprehensive Review and Clinical Experience

  2025cites this paper
• The BRAF‐specific region suppresses cysteine‐rich domain–lipid interaction independently of canonical autoinhibition by the 14‐3‐3 dimer

  2025cites this paper
• Kinase signaling cascades: an updated mechanistic landscape

  2025cites this paper
• Application of pretreatment 18F-FDG PET metabolic parameters in children with Langerhans cell histiocytosis

  2025cites this paper
• The many ways to inhibit translation by Sorafenib in liver cancer cells

  2025cites this paper
• Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study.

  2025cites this paper
• Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies

  2025cites this paper
• The “long-tongue” sign: a new perspective on magnetic resonance imaging images of medullary ganglioglioma

  2025cites this paper
• MutationAssessor in cBioPortal

  2025cites this paper
• Discovery of potential RAF selective back pocket as a promising biological site for BRAF inhibitors targeting resistant melanoma opens the door for a new generation of kinase inhibitors: Design, synthesis, biological evaluation, and in silico molecular simulation.

  2025cites this paper
• Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold

  2025cites this paper
• A novel in vivo phenotypic assay to evaluate kinase inhibitor induced cardiotoxicity and strategies for cardioprotection.

  2025cites this paper
• Quantitative Membrane Binding Assays Reveal an Inhibitory Role for the BRAF-Specific Region in CRD and Lipid Interaction

  2025cites this paper
• BRAF Mutation Status in Inflamed Juvenile Conjunctival Nevus, Primary Acquired Melanosis and Conjunctival Common Nevus.

  2025cites this paper
• Comprehensive analysis of regulated cell death pathways: intrinsic disorder, protein–protein interactions, and cross-pathway communication

  2025cites this paper
• Evaluation of the anti-angiogenic property of uvaol: in silico, in vitro, and in ovo approaches

  2025cites this paper
• Atraric acid increases the antitumor effect of BRAF inhibitor through the regulation of the HGK/MEK1/ERK signaling pathway.

  2025cites this paper
• Real time characterization of the MAPK pathway using native mass spectrometry

  2025cites this paper
• A Comprehensive Review of RAF Kinase: Advances in Inhibition Strategies for Drug Development

  2025cites this paper
• Association of phosphorylation status of ERK and genetic MAPK alterations in pediatric tumors

  2025cites this paper
• Mechanisms of resistance to active state selective tri-complex RAS inhibitors

  2025cites this paper
• Oncogenic mutations of clinical significance in colorectal cancer.

  2025cites this paper
• Targeting oncogenic signal pathway to improve cancer immunotherapy: Insights and perspectives.

  2025cites this paper
• Drug-Induced Sarcoid-like Reactions Associated to Targeted Therapies and Biologic Agents

  2025cites this paper
• Age-associated changes in type I collagen promote the invasion of BRAFV600E mutated melanoma cells and their resistance to targeted therapies within three-dimensional matrix models

  2025cites this paper
• Etiopathogenesis and Treatment of Colorectal Cancer

  2025cites this paper
• Value of a BRAFV600E and lymphocyte subset-based nomogram for discriminating benign lesions from papillary thyroid carcinoma in C-TIRADS 3 and higher nodules

  2025cites this paper
• Harnessing cuproptosis: a new avenue for targeted cancer therapies

  2025cites this paper
• Primary sellar glomus tumor with BRAF K601E mutation: an aggressive tumor of uncertain malignant potential.

  2025cites this paper
• The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review

  2025cites this paper
• HDAC11 Deacetylates BRAF to Regulate Kinase Activity and Cell Proliferation.

  2025cites this paper
• Gastrointestinal cancer: molecular pathogenesis and targeted therapy

  2025cites this paper
• Imaging Proliferation of Stage IV Cutaneous Melanoma With 18F-FLT PET/CT: A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?

  2025cites this paper
• Phosphorylation deficient inducible cAMP early repressor (ICER) modulates tumorigenesis and survival in a transgenic zebrafish (Danio rerio) model of melanoma

  2025cites this paper
• BRAF V600E in Cancer: Exploring Structural Complexities, Mutation Profiles, and Pathway Dysregulation.

  2025cites this paper
• One-pot synthesis and anti-proliferative activity of hindered 5-amino-1-alkylimidazole-4-carboxamides

  2025cites this paper
• Molecular Biomarkers in Borderline Ovarian Tumors: Towards Personalized Treatment and Prognostic Assessment

  2025cites this paper
• The paradoxical activity of BRAF inhibitors: potential use in wound healing.

  2025cites this paper
• Discovery of novel EGFR and BRAF inhibitors by machine learning approach

  2025cites this paper
• The Olive Oil Monophenolic Secoiridoid Ligstroside Aglycone Suppresses Melanoma Progression by Targeting the BRAF Signaling Pathway

  2025cites this paper
• Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening

  2025cites this paper
• Pyrazolopyrimidines: A Promising Frontier in Cancer Treatment‐Reviewing Their Potential as Inhibitors of Serine/Threonine Kinases

  2025cites this paper
• Skin Photodamage and Melanomagenesis: A Comprehensive Review

  2025cites this paper
• Conserved Gαq-PLCβ-PKC signaling mediates trametinib resistance in BRAFV600E melanoma

  2025cites this paper
• The Design, Synthesis, and Evaluation of the Biological Activity of Hydroxamic Derivatives of Sorafenib

  2025cites this paper
• Versatile Xenopus tropicalis model with targeted integration of human BRAFV600E

  2025cites this paper
• Acral Melanoma: A Review of Its Pathogenesis, Progression, and Management

  2025cites this paper
• PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers.

  2025cites this paper
• Exploration of Genetic Variants Associated with Lung Cancer: A Comprehensive Review

  2025cites this paper
• Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines

  2025cites this paper
• SQLE amplification accelerates esophageal squamous cell carcinoma tumorigenesis and metastasis through oncometabolite 2,3-oxidosqualene repressing Hippo pathway.

  2025cites this paper
• Identification of T cell dysfunction molecular subtypes and exploration of potential immunotherapy targets in BRAF V600E-mutant colorectal cancer

  2025cites this paper
• Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC

  2025cites this paper
• Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations

  2025influential citation
• 3,5-Disubstituted pyrazoline as a promising core for anticancer agents: mechanisms of action and therapeutic potentials.

  2025cites this paper
• Carvacrol-Derived 1,2,3-Triazole Hybrids: Synthesis, Computational Insights, and Targeted Inhibition of EGFR, BRAF V600E, and Tubulin Enzymes

  2025cites this paper
• BRAF mutation and neoadjuvant chemo-immunotherapy, is it worthwhile?

  2025cites this paper
• The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs

  2025cites this paper
• Systemic Therapies for Metastatic Melanoma.

  2025cites this paper
• Positive cooperativity between RAS-binding and cysteine-rich domains regulates RAF membrane binding kinetics via lateral rebinding

  2025cites this paper
• Design and synthesis of novel 2-S-alkylated Quinazolinones as dual BRAFV600E and EGFR inhibitors in melanoma: Mechanistic insights from apoptosis and cell cycle modulation.

  2025cites this paper
• Challenges and opportunities for the diverse substrates of SPOP E3 ubiquitin ligase in cancer

  2025cites this paper
• Therapeutic Approaches to Mucosal Melanoma.

  2025cites this paper
• Melanoma and Colorectal Cancer as Second Primary Cancers: A Scoping Review of Their Association and the Underlying Biological, Lifestyle, and Genetic Factors

  2025cites this paper
• BRAF inhibitors in Melanoma: Structural Insights, Therapeutic Resistance, and Biological Evaluation of Quinazoline Derivatives.

  2025cites this paper
• A comprehensive description of cyclin-dependent kinase 8 (CDK8) inhibitors as anticancer agents.

  2025cites this paper
• MAPK/ERK signaling pathway in rheumatoid arthritis: mechanisms and therapeutic potential

  2025cites this paper
• Treatment outcome of NSCLC patients with BRAFnon-V600E mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany

  2025cites this paper
• Mutation-specific structural changes in BRAF: understanding dimerization and drug binding for targeted therapy.

  2025cites this paper
• BRAF Mutation Analysis: A Retrospective Evaluation of 8365 Diagnostic Samples with a Special View on Canine Breeds (2018–2024)

  2025cites this paper
• Agnostic Biomarkers and Molecular Signatures in Colorectal Cancer—Guiding Chemotherapy and Predicting Response

  2025cites this paper
• Signaling from RAS to RAF: The Molecules and Their Mechanisms.

  2024cites this paper
• Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.

  2024cites this paper
• Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling

  2024cites this paper
• BRAF — a tumour-agnostic drug target with lineage-specific dependencies

  2024influential citation
• DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis

  2024cites this paper
• Recent advances in multitarget-directed ligands via in silico drug discovery.

  2024cites this paper
• Neuroblastoma and its Target Therapies: A Medicinal Chemistry Review

  2024cites this paper
• DeKinomics pulse-chases kinase functions in living cells

  2024cites this paper
• Conformational diversity and protein–protein interfaces in drug repurposing in Ras signaling pathway

  2024cites this paper
• A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation

  2024cites this paper
• Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node

  2024cites this paper
• Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways.

  2024cites this paper
• Progress in protein atlas of colorectal precancerous lesions

  2024cites this paper